Inozyme Pharma Inc (NASDAQ: INZY) on Monday, soared 10.07% from the previous trading day, before settling in for the closing price of $0.82. Within the past 52 weeks, INZY’s price has moved between $0.79 and $7.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 12.96%. With a float of $43.53 million, this company’s outstanding shares have now reached $64.24 million.
In an organization with 67 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Inozyme Pharma Inc (INZY) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Inozyme Pharma Inc is 32.23%, while institutional ownership is 59.11%. The most recent insider transaction that took place on Apr 02 ’25, was worth 7,849. In this transaction CEO & Chairman of this company sold 8,819 shares at a rate of $0.89, taking the stock ownership to the 41,046 shares.
Inozyme Pharma Inc (INZY) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.96% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.09% during the next five years compared to -13.98% drop over the previous five years of trading.
Inozyme Pharma Inc (NASDAQ: INZY) Trading Performance Indicators
Inozyme Pharma Inc (INZY) is currently performing well based on its current performance indicators. A quick ratio of 3.56 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.26 in one year’s time.
Technical Analysis of Inozyme Pharma Inc (INZY)
Let’s dig in a bit further. During the last 5-days, its volume was 0.52 million. That was inferior than the volume of 0.7 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 31.34%. Additionally, its Average True Range was 0.11.
During the past 100 days, Inozyme Pharma Inc’s (INZY) raw stochastic average was set at 5.33%, which indicates a significant decrease from 54.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.05% in the past 14 days, which was lower than the 93.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1684, while its 200-day Moving Average is $3.4713. However, in the short run, Inozyme Pharma Inc’s stock first resistance to watch stands at $0.9933. Second resistance stands at $1.0867. The third major resistance level sits at $1.2233. If the price goes on to break the first support level at $0.7633, it is likely to go to the next support level at $0.6267. The third support level lies at $0.5333 if the price breaches the second support level.
Inozyme Pharma Inc (NASDAQ: INZY) Key Stats
Market capitalization of the company is 58.06 million based on 64,240K outstanding shares. Right now, sales total 0 K and income totals -102,020 K. The company made 0 K in profit during its latest quarter, and -27,070 K in sales during its previous quarter.
